These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

9562 related articles for article (PubMed ID: 1782082)

  • 1. Interleukin-2 therapy for refractory and relapsing lymphomas.
    Tourani JM; Levy V; Briere J; Levy R; Franks C; Andrieu JM
    Eur J Cancer; 1991; 27(12):1676-80. PubMed ID: 1782082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K; Margolin K; Champlin R; Forman S
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study of autologous bone marrow transplantation followed by recombinant interleukin-2 in malignant lymphomas.
    Vey N; Blaise D; Tiberghien P; Attal M; Pico JL; Reiffers J; Harrousseau JL; Fiere D; Tabilio A; Gabus R; Brandely M; Maraninchi D
    Leuk Lymphoma; 1996 Mar; 21(1-2):107-14. PubMed ID: 8907277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
    Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA
    Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study.
    Geertsen PF; Hermann GG; von der Maase H; Steven K
    J Clin Oncol; 1992 May; 10(5):753-9. PubMed ID: 1569448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-2 treatment in lymphoma: a phase II multicenter study.
    Gisselbrecht C; Maraninchi D; Pico JL; Milpied N; Coiffier B; Divine M; Tiberghien P; Bosly A; Tilly H; Boulat O
    Blood; 1994 Apr; 83(8):2081-5. PubMed ID: 8161779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
    Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
    Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon.
    Besana C; Borri A; Bucci E; Citterio G; Di Lucca G; Fortis C; Matteucci P; Tognella S; Tresoldi M; Baiocchi C
    Eur J Cancer; 1994; 30A(9):1292-8. PubMed ID: 7999416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease.
    Younes A; Pro B; Robertson MJ; Flinn IW; Romaguera JE; Hagemeister F; Dang NH; Fiumara P; Loyer EM; Cabanillas FF; McLaughlin PW; Rodriguez MA; Samaniego F
    Clin Cancer Res; 2004 Aug; 10(16):5432-8. PubMed ID: 15328181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease.
    Silver RT; Case DC; Wheeler RH; Miller TP; Stein RS; Stuart JJ; Peterson BA; Rivkin SE; Golomb HM; Costanzi
    J Clin Oncol; 1991 May; 9(5):754-61. PubMed ID: 2016617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation.
    Nagler A; Ackerstein A; Or R; Naparstek E; Slavin S
    Blood; 1997 Jun; 89(11):3951-9. PubMed ID: 9166832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation.
    Nagler A; Berger R; Ackerstein A; Czyz JA; Diez-Martin JL; Naparstek E; Or R; Gan S; Shimoni A; Slavin S
    J Immunother; 2010 Apr; 33(3):326-33. PubMed ID: 20445353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?
    Josting A; Reiser M; Rueffer U; Salzberger B; Diehl V; Engert A
    J Clin Oncol; 2000 Jan; 18(2):332-9. PubMed ID: 10637247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinoma. Results of a multicenter SCAPP1 trial.
    Tourani JM; Lucas V; Mayeur D; Dufour B; DiPalma M; Boaziz C; Grise P; Varette C; Pavlovitch JM; Pujade-Lauraine E; Larregain D; Ecstein E; Untereiner M; Vuillemin E; Merran S; Andrieu JM
    Ann Oncol; 1996 Jul; 7(5):525-8. PubMed ID: 8839910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
    Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects.
    Vlasveld LT; Rankin EM; Hekman A; Rodenhuis S; Beijnen JH; Hilton AM; Dubbelman AC; Vyth-Dreese FA; Melief CJ
    Br J Cancer; 1992 May; 65(5):744-50. PubMed ID: 1586602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
    Bremer K
    J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of continuous intravenous infusion of recombinant interleukin-2 in patients with advanced renal cell carcinoma.
    Lopez M; Carpano S; Cancrini A; Marcellini M; Del Medico P; Rinaldi M; Vici P; Paoletti G; Di Lauro L
    Ann Oncol; 1993 Sep; 4(8):689-91. PubMed ID: 8241001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 479.